The Cambridge Cancer Centre is a dynamic collaboration of researchers, clinicians, and the pharmaceutical and biotech industries based in the Cambridge area. We combine world-class science and technology with excellent patient care to pioneer new ways to prevent, detect and treat cancer. By working together across different disciplines, we are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.
Patient care and clinical research
We offer a leading cancer care specialist service at Addenbrooke’s Hospital. We are committed to translating our clinical research to improve patient outcomes by recruiting the highest proportion of patients onto clinical trials in the UK.
Over 140 research groups work together across traditional academic, commercial and clinical boundaries. We connect cutting-edge science and technology from different disciplines to shed new light on preventing and controlling cancer.
Education and training
We educate and train the next generation of cancer scientists and clinicians. Working with the University of Cambridge we provide a stimulating learning environment for undergraduates, graduates, and postdoctoral researchers.
Cambridge will strengthen early detection research with a cash boost of £5 million for new Cancer Research UK Major Centre.
World-leading childhood brain tumour expert, Professor Richard Gilbertson has been appointed as the new Director of the Cambridge Cancer Centre.
Registration has now closed for the 2nd AstraZeneca-MedImmune Cambridge Cancer Science Symposium 21 – 22 September.
The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to Cambridge research published today.